Factors associated with low bone mineral density in a Brazilian cohort of vertically HIV-infected adolescents  by Schtscherbyna, Annie et al.
International Journal of Infectious Diseases 16 (2012) e872–e878Factors associated with low bone mineral density in a Brazilian cohort of vertically
HIV-infected adolescents
Annie Schtscherbyna a,*, Maria Fernanda Miguens Castelar Pinheiro b,
Laura Maria Carvalho de Mendonc¸a c, Carla Gouveia d, Ronir Raggio Luiz e,
Elizabeth Stankiewicz Machado d, Maria Lucia Fleiuss de Farias a
aDepartment of Endocrinology, Hospital Universita´rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro,
Alegre, 289/ 203 Jardim Guanabara, Rio de Janeiro, 21931-260 Brazil
b Endocrinology, Laborato´rio Se´rgio Franco, Rio de Janeiro, Brazil
cDepartment of Rheumatology, Hospital Universita´rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
dDepartment of Infectious Diseases Services, Hospital Universita´rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
e Institute of Public Health Studies, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
A R T I C L E I N F O
Article history:
Received 5 February 2012
Received in revised form 23 June 2012
Accepted 29 July 2012









S U M M A R Y
Objective: To assess the prevalence and factors associated with low bone mineral density (BMD) in HIV-
infected adolescents.
Methods: This was a cross-sectional study of a Brazilian cohort of vertically HIV-infected adolescents.
Body composition and lumbar spine (LS) and total body (TB) BMD were estimated by dual-energy X-ray
absorptiometry (DXA). Low BMD was considered for a Z-score 2 standard deviations. Pubertal
development, anthropometric data, laboratory measurements, antiretroviral regimen, and time of
immunological and virological recovery were evaluated as factors associated with a low BMD.
Results: Seventy-four adolescents aged 17.3  1.8 years were studied. Low BMD was present in 32.4% of
them. LS and TB BMD Z-scores were positively correlated with weight, body mass index (BMI), BMI Z-score,
total body fat, and nutritional status. Patients on tenofovir had lower LS and TB BMD Z-scores. Time on
tenofovir was indirectly correlated with LS and TB BMD Z-scores. No difference was found regarding levels of
calcium, parathyroid hormone, or 25-hydroxyvitamin D according to BMD status.
Conclusions: Control of the HIV infection, especially before the initiation of puberty, might have a
positive inﬂuence on bone gain. Body composition and nutritional status had a positive inﬂuence on
BMD that was more evident in females, suggesting that nutritional intervention may have a positive
impact on BMD.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Universal access to antiretroviral therapy (ART) and especially
to highly active antiretroviral therapy (HAART), which combines
drugs with different modes of action, has resulted in a signiﬁcant
decline in mortality rates, allowing many vertically HIV-infected
children to reach adolescence.1 This increasing survival rate is also
evident in Brazil, mostly since 1996 when the public health system
started the distribution of HAART.2
As a consequence, long-term complications of the HIV
infection and HAART side effects have been the focus of many
studies. A decrease in height-for-age has been described in* Corresponding author. Tel.: +55 21 88923303; fax: +55 22 27913875.
E-mail address: anniebyna@yahoo.com.br (A. Schtscherbyna).
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http://dx.doi.org/10.1016/j.ijid.2012.07.019HIV-infected children, and this difference in linear growth is
already signiﬁcant at the age of 15 months.3 HIV can infect bone
cells and alter bone metabolism, and patients fail to achieve the
expected gains in bone size, mass, and strength.4 ART may also
have direct and indirect effects on phosphate and vitamin D
metabolism, which contributes to low bone mineral density
(BMD) due to impaired mineralization.5 HIV patients may also
have hypovitaminosis D, even subclinical, which is now
recognized as one of the most important inﬂuences on skeletal
integrity.6
Due to the lack of studies addressing factors related to low BMD
in HIV-infected adolescents in Brazil, the aim of this study was to
assess the prevalence and factors associated with low BMD in a
cohort of vertically HIV-infected adolescents, followed-up at the
Clementino Fraga Filho University Hospital, at the Federal
University of Rio de Janeiro (HUCFF-UFRJ).ses. Published by Elsevier Ltd. All rights reserved.
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2.1. Study population
All vertically HIV-infected adolescents followed-up at the
Infectious Diseases Service of the HUCFF-UFRJ were considered
for this study. One patient was excluded due to neoplasia and two
refused participation. The remaining 74 selected patients were not
receiving bone-active drugs (glucocorticoids, anticonvulsants,
bisphosphonates, calcium, and vitamin D supplements), had no
hepatitis C virus co-infection or other detectable disease that could
affect bones, and denied drug addiction or alcohol consumption;
one was a current cigarette smoker. Pregnancy was excluded by b-
human chorionic gonadotropin (HCG) testing. Some patients had
been pregnant but were included: one patient at 6 months after
abortion and four patients at 12 months after parturition. Also,
opportunistic infections were controlled in two patients before
inclusion (pulmonary pneumocystosis and cerebral toxoplasmo-
sis). The study was performed during the period May 2008 to May
2011.
The diagnosis of perinatal HIV infection was retrospective, as
most of the children were the index case in the family, while others
were diagnosed by screening of a family index case. The mean age
at ﬁrst HIV test was 4.7  3.6 years. In 80% of the cases, the infection
was also conﬁrmed in the mother. In the remaining 20%, composed of
orphan children at the time of diagnosis, a history of HIV infection in
the mother could be retrieved, with the exception of three cases. Over
95% were breastfed, therefore we consider that most of the HIV
infections were acquired around peripartum or in the early postnatal
period.
The study protocol was approved by the Ethics Committee of
the HUCFF-UFRJ. Written informed consent was obtained from all
participants and their parents/guardians.
2.2. ART history and virological and immunological evaluations
ART was categorized into the following: (1) none; (2) dual
therapy (use of two nucleoside or nucleotide analogue reverse
transcriptase inhibitors (NRTIs)); and (3) HAART consisting of
NRTIs + non-nucleoside reverse transcriptase inhibitor (NNRTI) or
protease inhibitor (PI). The ART used at the time of the study and
previous exposure to dual therapy were considered. Time between
birth and initiation of treatment, time on ART (deﬁned as the time
between the initiation of any antiretroviral and the time of the
dual-energy X-ray absorptiometry (DXA) exam), time on tenofovir
(TDF), time of undetectable viral load (viral load <50 copies/ml),
time between birth and the ﬁrst undetectable viral load, and CD4+
<200 cells/mm3 were analyzed. Immunological stage was deter-
mined according to the US Centers for Disease Control and
Prevention (CDC) classiﬁcation system.7
2.3. Laboratory measurements
Blood was drawn after overnight fasting for routine exams
(hemogram, glucose, calcium, phosphorus, albumin, creatinine,
and liver enzymes). Calcium was corrected for albumin levels
(Cacorr = Ca + 0.8  [4  alb]). Other exams were CD4+ cell counts
measured by FACSCalibur (Becton-Dickinson, NJ, USA) and viral
load by bDNA (Versant HIV-1 RNA 3.0 third generation, Chiron/
Bayer/Siemens; the lower limit of detection was 50 copies/ml).
Serum samples were collected with protection from light and
stored at 80 8C until analysis of hormones: 25-hydroxyvitamin D
(25(OH)D) by high-performance liquid chromatography (HPLC;
Chromsystem, Germany; normal range 30–80 ng/ml) and intact
parathyroid hormone (PTH) by chemiluminescence (Immulite
2000, Siemens, USA; normal values 12–65 pg/ml).2.4. Assessment of BMD and body composition
DXA scans were performed on the lumbar spine (LS) and total
body (TB) to assess BMD and body composition (percent body fat
and lean mass), using Prodigy software v. 11.40, adequate for child
and adolescent assessment. The BMD Z-score was considered the
best measure to compare all patients because the population
included male and female patients of different ages. Lower than
expected BMD was deﬁned as Z-scores at LS and/or TB equal to or
lower than 2 standard deviations from the reference data (Z-score
2 SD).8
Weight, height, and body mass index (BMI) were used as
indicators. BMI-for-age was classiﬁed as follows: obesity (Z-score
>2), overweight (Z-score 2 to >1), normal (Z-score 1 to 2),
thinness (Z-score <2 to 3), severe thinness (Z-score <3), in
accordance with the World Health Organization (WHO) 2007
reference.9
2.5. Assessment of pubertal development
Pubertal stage was self-assessed privately using a validated
method with Tanner diagrams.10 Subjects were given a standard-
ized series of drawings showing the ﬁve developmental stages
with explanatory text to assess their own pubertal development.
2.6. Dietary intake
The dietary assessment was based on a single 24-h recall
conducted by a trained registered nutritionist, using measuring
cups, spoons, and portion-size images to increase the accuracy of
the recall. The household measurements were converted into
grams and milliliters for quantitative analysis of energy and
nutrient intake using the software Avanutri online (version online;
2010, Rio de Janeiro, Brazil). Only energy, macronutrients
(carbohydrate, protein, and lipid), calcium, and vitamin D results
are presented here. Calcium and vitamin D consumption were
categorized according to the estimated average requirement
(EAR).11
2.7. Statistical analysis
The Mann–Whitney test was employed to verify statistical
differences in continuous variables and Fisher’s exact test for
categorical variables. Spearman’s coefﬁcients between continuous
variables and BMD Z-scores at LS and TB were calculated. The level
of signiﬁcance adopted was p < 0.05. Analyses were performed
using SPSS v. 17.0 (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Demographic data and clinical, virological, and immunological
characteristics of the studied population
We studied 41 females and 33 males. Their mean age was
17.3  1.8 years (range 13.4–21.2 years). Because the Brazilian
population is highly mixed, we classiﬁed the race as white (36.5%) and
non-white (63.5%). At the time of evaluation, six of the patients were
off therapy, one was on two NRTIs, and 67 (90.5%) were on HAART: 14
(18.9%) on NRTIs + NNRTI and 53 (71.6%) on NRTIs + PI. Antiretroviral
therapy history, analyzed in 70 patients (48 normal BMD and 22 low
BMD), revealed that the majority, 53 patients (75.7%), had previous
exposure to two NRTIs; 32 (45.7%) had been exposed to TDF and 29
were currently using TDF (for 2.9  1.5 years). Patients were 6.3  3.8
years old at initiation of ART and the duration of treatment was
11.1  3.5 years. Virological and immunological evaluations analyzed
in 71 patients (48 normal BMD and 23 low BMD) demonstrated that
A. Schtscherbyna et al. / International Journal of Infectious Diseases 16 (2012) e872–e878e874viral load was undetectable in 34 patients (47.9%) during the last
3.8  2.9 years, and CD4+ was <200 cells/mm3 in 16 patients (22.5%).
3.2. Bone mineral density, use of antiretroviral therapy, and
laboratory measurements
No patient made reference to fragility fractures, bone pain, or
deformities. LS and/or TB BMD were low in 24 of the 74 patients
(32.4%), 23 of whom were receiving ART. Mean BMD Z-scores at LS
and TB were compared to the following variables: use of dual
therapy, TDF, PI, and presence of undetectable viral load. Patients
exposed to TDF showed a lower BMD Z-score at LS (1.82  1.12 vs.
1.28  0.93, p = 0.021) and TB (1.51  1.09 vs. 0.88  1.04,
p = 0.022). Patients on PI tended to show a lower BMD Z-score at
LS (1.74  1.09 vs. 1.12  0.95, p = 0.055), but not at TB
(1.31  1.12 vs. 0.88  1.10, p = 0.163). When analyzing patients
according to BMD status (normal or low BMD), the only signiﬁcant
differences were related to use and time on TDF and serum
phosphorus, and these were the only signiﬁcant differences for
ART and laboratory measures (Table 1). Patients on TDF compared to
those who had never used this drug had similar levels of serum
phosphorus (4.23  0.80 mg/dl vs. 4.17  0.96 mg/dl, p = 0.723) and a
lower BMD Z-score at LS (1.85  1.12 vs. 1.29  0.93, p = 0.019)
and TB (1.53  1.10 vs. 0.88  1.05, p = 0.019). Time on TDF was
inversely correlated to BMD Z-score at LS (r = 0.446; p = 0.013) and
TB (r = 0.383; p = 0.037). In relation to anthropometry, patients on
TDF showed a trend for a lower BMI Z-score (0.76  1.18 vs.
0.18  0.92, p = 0.093). However, time on TDF did not show any
correlation with the BMI Z-score. Although we found that low BMD
was independently associated with BMI and TDF exposure, the model
was unstable because of the small sample size.
Most patients with an undetectable viral load and a good
immunological CDC classiﬁcation had normal BMD Z-scores when
compared to those with less control over the HIV infection,
although this difference was not statistically signiﬁcant. Other
clinical parameters such as time from birth to initiation of
treatment, time on ART, and time of undetectable viral load, as wellTable 1
Laboratory measurements, antiretroviral therapy history, and virological and immunolog
HIV-infected adolescentsa.
Variables 
Use of PI 
Use of TDF 
Time on TDF, years 
Previous use of two NRTIs 
Time between birth and initiation of treatment, years 
Time between birth and the ﬁrst undetectable viral load, years 
Use of ART 
Time on ART, years 
CD4+ cell count, cells/mm3
CD4+ cells <200/mm3
Viral load, log10 copies/ml 
Undetectable viral load 
Time of undetectable viral load, years 








25-Hydroxyvitamin D, ng/ml 
ART, antiretroviral therapy; BMD, bone mineral density; Cacorr, calcium corrected for al
Prevention; NRTIs, nucleoside or nucleotide analogue reverse transcriptase inhibitors; 
a Results are presented as n (%) or mean  standard deviation.
b Antiretroviral therapy history was analyzed in 70 patients (48 normal BMD and 22 low
normal BMD and 23 low BMD).as serum 25(OH)D and PTH were not associated with the BMD Z-
scores or gender.
3.3. Bone mineral density, demographics, pubertal development, and
anthropometric data
Body composition and nutritional status were positively
associated with BMD Z-scores, especially in females (Table 2). A
low BMD Z-score was identiﬁed in 11 of the 17 (64.7%) patients
classiﬁed as ‘thinness’ or ‘severe thinness’, and only in 13 of 57
(22.8%) patients classiﬁed as ‘normal’ or ‘overweight’, although we
did not observe differences in the percentages of thinness and
severe thinness between the genders (data not shown). The
pubertal development group tended to be associated with BMD
status. All four patients with pubertal delay (Tanner stage 2) had an
age range of 15.4–17.6 years and Z-scores between 2 and 3.8
SD. We also observed a statistically signiﬁcant difference in the
presence of Tanner stage 5 among females (22/35, 62.9%) and
males (6/30, 20.0%) (p = 0.001). The one cigarette smoker had a
normal BMD.
Anthropometric data and correlation with BMD are presented
in Figure 1. The LS BMD Z-score tended to correlate with percent
body fat (r = 0.203, p = 0.083). The TB BMD Z-score tended to
correlate with percent body fat (r = 0.224, p = 0.055) and lean body
mass (r = 0.200, p = 0.087), and inversely with time between birth
and ﬁrst undetectable viral load (r = 0.339, p = 0.050). The height
Z-score was not correlated to BMD Z-scores.
Race did not inﬂuence the results of BMD in the group. Low
BMD was found in 37% of white and 29.8% of non-white patients
(p = 0.609). Z-scores of LS and TB for whites and non-whites were
1.63  1.21 vs. 1.44  0.98, p = 0.271 and 1.17  1.26 vs.
1.14  0.99, p = 0.682, respectively.
3.4. Bone mineral density and dietary intake
Dietary assessment data were not different between patients






33 (66) 20 (83.3) 0.100
18 (37.5) 14 (63.6) 0.037
2.4  1.2 3.6  1.4 0.019
38 (79.2) 15 (68.2) 0.241
6.5  3.6 6.0  4.2 0.558
12.3  4.3 14.9  2.1 0.149
45 (90) 23 (95.8) 0.360
11.0  3.6 11.1  3.5 0.746
479.3  318.3 438.0  287.3 0.326
12 (25.0) 4 (17.4) 0.556
2.2  2.0 1.8  1.9 0.290
22 (45.8) 12 (52.2) 0.466
4.4  3.3 2.9  1.7 0.302
0.089
3 (6.3) 0
12 (25.0) 3 (13.0)
33 (68.7) 20 (87.0)
37.3  27.0 35.7  15.8 0.716
3.9  0.8 4.6  0.8 0.014
9.2  0.9 8.9  0.8 0.223
5.8  6.1 4.5  0.4 0.359
37.1  10.3 40.2  18.2 0.490
bumin levels (Cacorr = Ca + 0.8  [4  alb]); CDC, US Centers for Disease Control and
PI, protease inhibitor; PTH, parathyroid hormone; TDF, tenofovir.
 BMD); virological and immunological evaluations were analyzed in 71 patients (48
Table 2
Demographic and anthropometric data in relation to bone mineral density status according to gender in a Brazilian cohort of vertically HIV-infected adolescentsa.














Female:male ratio 28:22 13:11 0.882
Age, years 17.4  2.0 17.2  1.3 0.673 17.4  1.9 17.3  1.3 0.833 17.4  2.1 17.1  1.3 0.789
Weight, kg 54.4  9.5 47.6  8.7 0.003 53.9  8.5 45.4  8.8 0.012 55.0  10.9 50.2  8.2 0.089
Height, m 1.59  0.10 1.58  0.07 0.738 1.55  0.05 1.56  0.06 0.790 1.65  0.12 1.62  0.07 0.078
Height-for-age, Z-score 1.03  1.02 1.29  0.96 0.183 0.97  0.64 0.98  1.00 0.846 1.11  1.34 1.62  0.07 0.138
BMI, kg/m2 21.4  3.1 18.9  2.9 0.004 22.4  3.3 18.8  3.3 0.007 20.1  2.3 19.1  2.4 0.252
BMI-for-age, Z-score 0.20  0.82 0.91  1.25 0.059 0.09  0.8 1.07  1.5 0.041 0.54  0.7 0.73  0.9 0.651
Lean body mass, kg 38.9  8.3 34.6  11.9 0.166 33.6  3.0 27.6  10.2 0.038 45.6  8.0 42.9  7.8 0.181
Total body fat, % 23.0  11.9 18.6  9.0 0.133 31.6  8.2 25.5  5.6 0.015 12.0  4.4 10.4  3.8 0.311
Total body fat, kg 12.6  7.6 8.6  4.7 0.038 17.2  6.7 11.6  4.3 0.014 6.8  3.7 5.1  1.9 0.143
Nutritional status <0.001 0.004 0.048
Severe thinness 0 8 (33.3) 0 5 (38.5) 0 3 (27.3)
Thinness 6 (12) 3 (12.5) 2 (7.1) 1 (7.7) 4 (18.2) 2 (18.2)
Normal 35 (70) 12 (50) 18 (64.3) 6 (46.1) 17 (77.3) 6 (54.5)
Overweight 9 (18) 1 (4.2) 8 (28.6) 1 (7.7) 1 (4.5) 0
Obesity 0 0 0 0 0 0
Pubertal developmentb 0.087 0.376 0.166
Tanner stage 1–2 1 (2.4) 4 (17.4) 0 1 (8.3) 1 (5.3) 3 (27.3)
Tanner stage 3–4 20 (48.8) 11 (47.8) 7 (31.8) 4 (33.3) 13 (68.4) 7 (63.6)
Tanner stage 5 20 (48.8) 8 (34.8) 15 (68.2) 7 (58.4) 5 (26.3) 1 (9.1)
BMD, bone mineral density; BMI, body mass index.
a Results are presented as n (%) or mean  standard deviation.
b Pubertal development was analyzed in 64 patients.
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respectively, but were not associated with BMD status. Patients
with an undetectable viral load consumed more energy
(3248.1  1298.8 kcal vs. 2736.4  1460.1 kcal, p = 0.037), carbohy-
drate (448.3  209.7 g vs. 336.9  149.8 g, p = 0.011), and calcium
(896.8  581.6 mg vs. 719.5  793.1 mg, p = 0.041).
4. Discussion
Despite the steady increase in studies evaluating bone loss in
HIV patients, most have not included adolescents. To our
knowledge, this is the ﬁrst study evaluating factors related to
low BMD in adolescents perinatally infected by HIV-1 in Latin
America.
Adolescence is characterized by an accelerated bone turnover,
but formation must exceed resorption to guarantee a progressive
bone gain until peak bone mass is achieved. Any chronic disease
during this period may compromise bone gain or even induce bone
loss.12 This may be true in HIV-infected adolescents exposed to
malnutrition, opportunistic infections, and long-term antiviral
therapy.
The current WHO deﬁnition of osteopenia and osteoporosis in
adults cannot be applied to children and adolescents because they
have not reached peak bone mass. For this reason, some authors
prefer not to classify bone status in children or adolescents.13 Our
patients were classiﬁed as having low BMD according to the 2007
International Society for Clinical Densitometry Pediatric Ofﬁcial
Positions.8 We found a high prevalence of low BMD among
vertically HIV-infected adolescents, as almost a third of the
patients had a low BMD Z-score at LS and/or TB. In 28 normal
female adolescents of similar age range, ethnicity, social condi-
tions, and nutritional status we previously identiﬁed that only two
had BMD Z-scores at or below 2 SD,14which is very different from
the prevalence of low BMD in these HIV-infected patients.
Different criteria are applied in studies with young seropositive
patients, which make it difﬁcult to compare these with our
ﬁndings. Gafni et al.,12 studying children 8–16 years of age, found
that 40% had low BMD Z-scores (<2 SD), however measurements
included not only LS and TB but also the femoral neck. Ramoset al.,15 studying 35 vertically HIV-infected children, found that
40% of the patients had osteopenia (BMD Z-score <1 SD for LS).
McComsey and Leonard,16 studying 23 vertically infected children,
found that 48% had osteoporosis (BMD Z-scores 2 SD) and 26%
met the criteria for osteopenia (BMD Z-scores <1 and >2 SD) at
LS.
HIV infection of osteoblasts may be related to a negative
balance of bone remodeling.5,17 The BMD of naı¨ve HIV-infected
patients seems to be lower than that in healthy controls, but this
difference disappears after adjustment for age, height, lean mass,
and fat mass.13 In our sample, only six patients were not using ART
and only one had a low BMD, a proportion apparently lower than
that seen in the treated group (23 out of 68). However, the small
sample precludes any further analysis.
Bone loss is expected after initiation of ART in adult
populations,18 but there is a lack of longitudinal studies regarding
the impact of ART on BMD in young populations. A comparison
between HAART-treated and HAART-naı¨ve children has shown
that HAART was a risk factor for low BMD.13 PIs have been related
to increased bone turnover, accelerated bone loss, and a higher
prevalence of reduced BMD.12,18 Some studies comparing bone loss
with PIs or NNRTIs have associated the use of PIs with a greater loss
of BMD,17–19 but other studies have failed to show such a
difference.20,21 Although in our study a comparison between PIs
and NNRTIs was not possible because of the small number of
patients using NNRTIs, patients on PIs tended towards lower LS
BMD, but not at TB. This could be explained by the higher turnover
rates in trabecular bone, mainly involved in the maintenance of
mineral homeostasis which predominates in vertebrae, when
compared to the cortical bone responsible for support functions
which composes most of the human skeleton.5
TDF has been associated with renal and bone toxicity in
children,22 with decreased renal tubular phosphate reabsorption
leading to hypophosphatemia and decreased bone mineraliza-
tion,23 but the impact on BMD is still controversial. In a study of a
48-week treatment in children and adolescents, TDF was
associated with a >6% decline in BMD Z-score in a third of the
subjects. Decreases in BMD correlated with young age, suggesting
that these patients may be at greater risk of bone toxicity,22
Figure 1. Scatter plot and correlation coefﬁcients from parameters that inﬂuence bone mineral density in a Brazilian cohort of vertically HIV-infected adolescents.
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study found low BMD in 40% of children treated with TDF.12
Results of the present study reinforce the relationship between
TDF and low bone mass, despite no signiﬁcant alteration in
phosphate metabolism. In fact, we found higher serum phosphorus
among patients with low bone density, but the reason for this
ﬁnding is unknown. We also found that time on TDF showed a
trend to correlate with low BMD Z-scores. On the other hand, some
studies have failed to show any correlation between TDF and low
bone mass, even after long-term exposure to the drug.25,26
NRTIs can reduce BMD by elevating lactic acidemia, a
mechanism related to calcium hydroxyapatite loss, especially in
the trabecular bone, due to the lability of calcium storage.27 Our
study did not ﬁnd differences in BMD Z-scores when comparing
adolescents treated with two NRTIs before the introduction of
HAART.
Several studies have directly highlighted HIV factors associated
with low BMD, especially: duration of infection, HIV viral burden,
and a more advanced HIV disease (reﬂected by a lower CD4+).28
Our patients who achieved an undetectable viral load at an earlier
age tended to have a better TB BMD Z-score, suggesting that
control of the HIV infection, especially before the initiation of
puberty, might have a positive inﬂuence on bone gain. Recent
treatment guidelines for HIV-infected children suggest the
initiation of HAART before 1 year of age, but early initiation of
treatment can expose children to the negative inﬂuence HAART has
on bones. Thus it will be interesting in the future to assess BMD in
this group of children to evaluate the impact of earlier treatment
on bone health.
Vitamin D and PTH are also related to bone health. Vitamin D
deﬁciency has the potential to cause osteomalacia or accelerated
bone loss due to secondary hyperparathyroidism.29 In our sample
these hormones did not seem to inﬂuence BMD.
Delayed sexual maturity has also been observed in perinatally
infected children and adolescents.30,31 During pubertal develop-
ment a signiﬁcant gain in bone mass is directly correlated to age,
height, and weight through childhood, and differences between
genders become evident. Both the starting age of the pubertal spurt
and growth process are earlier in girls, but the duration of the
growth spurt and the maximal peak of growth are greater in
boys.32 Approximately one-third of bone mass is accumulated
between pubertal stages 2 and 5, especially in cancellous bone.33 A
study comparing HIV-infected adolescents and controls showed no
difference in bone mass at Tanner stage 1–2 for either boys or girls,
but a pronounced difference in later Tanner stages in boys.
According to that study, infected boys and girls may acquire a
similar amount of bone mass as those not infected, but at a later
age.31 In our study there was no control group. However, there was
a trend to lower BMD Z-scores in early pubertal stages as compared
to stage groups 3–4 and 5, suggesting that pubertal delay was an
important factor for these HIV patients.
Many confounding factors are assumed to play a role in the
pathogenesis of decreased bone mass in HIV/AIDS patients.34
Studies evaluating speciﬁc body composition determinants and
bone mineral show contradictory results. A 10-year longitudinal
study found that the fat-free mass is the most important
component of body composition that inﬂuences LS bone in young
adulthood.35 However, according to Reid,36 between the determi-
nants of BMD in humans, low weight appears to be the major
component, and this relationship has also been identiﬁed in HIV
patients.4,37 Our results are in agreement with these ﬁndings,
showing a positive inﬂuence of body composition on BMD. Weight,
BMI, and body fat were associated with BMD, especially in females.
A possible explanation for this ﬁnding could be the higher
distribution of Tanner stage 5 among females when compared
to males. These ﬁndings reinforce the importance of a healthynutritional status in adolescents perinatally infected by HIV-1 to
prevent low BMD.
Food consumption is another important factor for bone mineral
accrual, especially because low calcium and vitamin D intake
reduce BMD.38 We detected important inadequacies in the intake
of bone health-related nutrients in the adolescent HIV population,
although calcium and vitamin D intake were similar to that
described in other young Brazilian populations.14,39 Overall
nutritional status had a positive inﬂuence on bone and this might
explain the trend for higher BMD in those patients with
undetectable viral load, who also had a better diet in relation to
energy, carbohydrate, and calcium. Dietary intake was determined
by a single 24-h recall, so these values are only an estimate. Larger
studies are clearly needed to better characterize the habitual
intake of this population. Another limitation of our study is the lack
of information regarding physical activity in the group studied.
In conclusion, we detected a high prevalence of low BMD
among vertically HIV-infected adolescents. Among all possible risk
factors demonstrated in the literature for bone loss in HIV patients,
in our sample low BMD was associated with body composition,
especially in females, and to the use of TDF. Besides that, control of
the HIV infection, especially before the initiation of puberty, might
have a positive inﬂuence on bone gain.
All HIV-infected adolescents in whom undernutrition is
clinically observed should be screened for low BMD. This will
lead to the identiﬁcation of patients at great risk of skeletal
fractures and guide treatment decisions. Attempts to improve
nutritional status and an adequate intake of calcium and vitamin D
may be beneﬁcial to those with low BMD, which in turn correlates
with a longer life expectancy and a better quality of life.
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